Ravulizumab in myasthenic crisis: the first case report

J Neurol. 2024 May;271(5):2898-2901. doi: 10.1007/s00415-024-12234-2. Epub 2024 Feb 23.

Authors

Franz Felix Konen¹, Konstantin Fritz Jendretzky¹, Dominica Ratuszny¹, Ramona Schuppner¹, Kurt-Wolfram Sühs¹, Marc Pawlitzki², Tobias Ruck², Sven G Meuth², Thomas Skripuletz³

Affiliations

¹ Department of Neurology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany.
² Department of Neurology, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University, Moorenstraße 5, 40225, Duesseldorf, Germany.
³ Department of Neurology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany. Skripuletz.thomas@mh-hannover.de.

PMID: 38388927
DOI: 10.1007/s00415-024-12234-2

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use
Female
Humans
Male
Middle Aged
Myasthenia Gravis* / drug therapy

Substances

Antibodies, Monoclonal, Humanized